1 00:00:02,951 --> 00:00:03,641 Sara Dong: Hi everyone. 2 00:00:03,701 --> 00:00:08,111 Welcome to Febrile, a cultured podcast about all things infectious disease. 3 00:00:08,511 --> 00:00:12,621 We dive into ID clinical reasoning, diagnostics and antimicrobial management. 4 00:00:12,981 --> 00:00:14,811 I'm Sara Dong, your host. 5 00:00:15,261 --> 00:00:20,571 I am super excited to have a special collab with Neph Madness today. 6 00:00:20,881 --> 00:00:24,481 We have several guests joining us, so I'm gonna let them introduce themselves, 7 00:00:24,778 --> 00:00:25,947 Caitlyn, maybe I'll start with you. 8 00:00:27,571 --> 00:00:28,901 Caitlyn Vlasschaert: Hi, I'm Caitlyn Vlasschaert. 9 00:00:28,921 --> 00:00:32,191 I'm a fourth year nephrology fellow at Queens University up 10 00:00:32,191 --> 00:00:33,686 in Kingston, Ontario, Canada. 11 00:00:34,657 --> 00:00:35,407 Hariharasudan Natarajan: Hello everyone. 12 00:00:35,407 --> 00:00:36,067 I'm Hari. 13 00:00:36,067 --> 00:00:39,637 I'm currently a second year nephrology fellow at Mount Sinai Hospital. 14 00:00:39,877 --> 00:00:41,287 I'm excited to be here today. 15 00:00:42,302 --> 00:00:43,802 Jeannina Smith: Hi, I'm Jeannina Smith. 16 00:00:43,802 --> 00:00:48,352 I am an infectious disease specialist in transplantation. 17 00:00:48,352 --> 00:00:51,172 I'm the Medical Director of Transplant Infectious Disease at the University of 18 00:00:51,172 --> 00:00:55,802 Wisconsin, and I am very excited to be here to talk about one of my very favorite 19 00:00:55,802 --> 00:00:57,692 subjects, the troll of transplant. 20 00:00:57,970 --> 00:00:58,640 Sam Kant: I'm Sam Kant. 21 00:00:58,660 --> 00:01:01,720 I'm a transplant nephrologist at St. Vincent's University 22 00:01:01,720 --> 00:01:05,450 Hospital, Dublin, which is, within the University College Dublin. 23 00:01:05,450 --> 00:01:06,940 So thanks for having us, Sara. 24 00:01:08,156 --> 00:01:09,456 Samira Farouk: Hi, I am Samira Farouk. 25 00:01:09,476 --> 00:01:12,686 I'm a transplant nephrologist and program director of the Nephrology Fellowship 26 00:01:12,686 --> 00:01:14,786 program at Mount Sinai in New York City. 27 00:01:15,276 --> 00:01:18,046 Um and relevant for this, I've been part of the Neph Madness Executive 28 00:01:18,046 --> 00:01:20,716 Committee for the last several years, and really thrilled to be here. 29 00:01:20,716 --> 00:01:23,566 And thank you to the Febrile podcast for hosting us. 30 00:01:24,866 --> 00:01:28,586 Sara Dong: Before we jump into Neph Madness, we always ask one question. 31 00:01:28,826 --> 00:01:32,941 As everyone's favorite cultured podcast, if you could share a little piece of 32 00:01:32,941 --> 00:01:37,375 culture, just something fun, non-work, related that brings you happiness. 33 00:01:37,735 --> 00:01:39,775 Jeannina Smith: I just did a [The] Pitt marathon. 34 00:01:40,090 --> 00:01:44,230 Um, and though I found it like sort of stressful, it's also sort 35 00:01:44,230 --> 00:01:49,640 of relaxing to see medical cases where I don't have to respond. 36 00:01:49,970 --> 00:01:56,550 Uh, so, uh, I did a, a major like four hour Pitt binge fest just 37 00:01:56,550 --> 00:01:58,530 yesterday and uh, it was a good one. 38 00:01:58,646 --> 00:01:59,576 Sara Dong: Very nice. 39 00:02:00,426 --> 00:02:03,276 Samira Farouk: I am a huge, uh, sports fan and will watch any sport, 40 00:02:03,316 --> 00:02:04,516 particularly love women's sports. 41 00:02:04,516 --> 00:02:05,806 Been watching a ton of Olympics. 42 00:02:06,309 --> 00:02:09,039 It's gotten very stressful in the figure skating arena, so 43 00:02:09,039 --> 00:02:10,389 taking a little bit of a break. 44 00:02:10,809 --> 00:02:13,569 But any sport on TV will be my kind of go-to. 45 00:02:14,026 --> 00:02:16,126 Jeannina Smith: Some of the women athletes had a pretty good quote. 46 00:02:16,126 --> 00:02:19,216 They said, why is it focusing so much on women's competitions? 47 00:02:19,216 --> 00:02:19,846 And they said, when? 48 00:02:19,906 --> 00:02:23,356 When the men get as many gold medals as the US women, perhaps 49 00:02:23,356 --> 00:02:24,526 their coverage will match. 50 00:02:28,739 --> 00:02:29,069 Caitlyn Vlasschaert: Yeah. 51 00:02:29,069 --> 00:02:33,839 I'd say for me, I'm a huge classic rock fan and a lot of my travels 52 00:02:33,839 --> 00:02:37,379 and sort of activities center around trying to make it to a concert. 53 00:02:37,649 --> 00:02:41,189 Usually people's last concerts as they're doing a farewell tour. 54 00:02:42,209 --> 00:02:44,939 Samira Farouk: I saw Fleetwood Mac's 50th anniversary concert. 55 00:02:44,939 --> 00:02:47,759 Best concert ever been to, I hope they don't tour again. 56 00:02:47,759 --> 00:02:49,734 So that's like I saw the last round. 57 00:02:51,291 --> 00:02:54,859 Hariharasudan Natarajan: So, growing up in Southern India, I am deeply passionate 58 00:02:54,859 --> 00:02:59,269 about South Indian cuisine, and I believe it's the best food in the world. 59 00:02:59,329 --> 00:03:03,594 I am constantly on lookout for the best South Indian restaurant in New York City. 60 00:03:04,014 --> 00:03:07,909 And if you are ever in this part of the country and you need recommendations, 61 00:03:07,909 --> 00:03:09,979 I will be delighted to help you out. 62 00:03:10,804 --> 00:03:13,114 Sara Dong: I will take those recommendations later. 63 00:03:14,494 --> 00:03:16,504 Well thank you guys so much for joining. 64 00:03:16,504 --> 00:03:20,704 It's so fun, obviously, uh, Febrile we tend to have a lot of ID 65 00:03:20,704 --> 00:03:22,324 guests, so it's nice to have a mix. 66 00:03:22,324 --> 00:03:24,384 We have some kidney folks with us today. 67 00:03:24,384 --> 00:03:27,504 For those who aren't familiar, Samira, could you give listeners an 68 00:03:27,504 --> 00:03:30,414 overview of what Neph Madness is? 69 00:03:30,754 --> 00:03:32,124 And how to participate? 70 00:03:32,807 --> 00:03:33,677 Samira Farouk: Yeah, definitely. 71 00:03:33,677 --> 00:03:36,977 Um, so just before we get into it, I think for people that are familiar 72 00:03:36,977 --> 00:03:40,487 with Neph Madness and the nephrology community, Neph Madness is a very 73 00:03:40,487 --> 00:03:42,041 special, exciting time of year. 74 00:03:42,041 --> 00:03:43,511 It's almost like the holidays. 75 00:03:43,791 --> 00:03:45,801 And so we're really fired up getting close to it. 76 00:03:46,021 --> 00:03:50,081 So it's an annual online educational initiative, which, uh, when it 77 00:03:50,081 --> 00:03:54,241 was started and how it was named is, inspired by March Madness. 78 00:03:54,241 --> 00:03:57,931 And so for those of you that might not know, March Madness is a US 79 00:03:57,961 --> 00:04:01,501 college basketball competition where college teams are pitted against 80 00:04:01,501 --> 00:04:04,561 each other in a bracket, and then at the end you have one winner. 81 00:04:04,811 --> 00:04:09,951 So kind of take that bracket, replace geographic regions with nephrology 82 00:04:09,951 --> 00:04:14,666 topics and replace those teams with subtopics within those regions. 83 00:04:14,696 --> 00:04:19,866 And so, we ultimately have a bracket of 16 topics, and to play Neph Madness, 84 00:04:19,866 --> 00:04:23,826 your job is to read our scouting reports about each of those topics, 85 00:04:23,856 --> 00:04:27,676 and then complete your bracket to pick a winner for each section and then 86 00:04:27,676 --> 00:04:29,386 eventually a winner for the competition. 87 00:04:29,716 --> 00:04:30,616 So how do you win? 88 00:04:30,706 --> 00:04:35,206 Uh, you want your bracket to match that of our Blue Ribbon panels bracket. 89 00:04:35,326 --> 00:04:39,556 So that's a group of experts from around the world, patients we try 90 00:04:39,556 --> 00:04:41,386 to represent as much as we can. 91 00:04:41,902 --> 00:04:45,082 They actually complete their voting before the tournament begins on 92 00:04:45,082 --> 00:04:48,412 March 1st, so we know what the right answer is before we start. 93 00:04:48,412 --> 00:04:52,192 It's in a special locked envelope somewhere that I don't have access to. 94 00:04:52,552 --> 00:04:55,882 Um, and during the month of March, the goal is to not only complete 95 00:04:55,882 --> 00:05:00,322 your brackets at nephmadness.com, but also to learn about these topics, 96 00:05:00,322 --> 00:05:03,772 to talk about these topics in your favorite social media platform. 97 00:05:04,012 --> 00:05:07,581 Uh, many fellowship and residency programs, uh, will have sessions 98 00:05:07,581 --> 00:05:09,231 where they go through these brackets. 99 00:05:09,421 --> 00:05:12,451 Um, our team actually puts together a pre-made slide set that you 100 00:05:12,451 --> 00:05:15,817 can use if you're interested in hosting a session at your program. 101 00:05:15,817 --> 00:05:19,537 And, uh, we've also had some friendly fellowship, fellowship competition 102 00:05:19,566 --> 00:05:21,711 once the bracket results get announced. 103 00:05:22,041 --> 00:05:24,891 So, uh, we're here today to talk about one of the sections. 104 00:05:24,891 --> 00:05:27,681 As a transplant nephrologist today is the transplant region. 105 00:05:27,711 --> 00:05:31,941 And I will say that I've been a part of Neph Madness, uh, since I think 2019. 106 00:05:31,941 --> 00:05:35,061 And I have been begging for these two teams to get into the tournament 107 00:05:35,061 --> 00:05:38,431 and they finally let them in, mainly because of some of the exciting 108 00:05:38,431 --> 00:05:39,781 things that are happening with them. 109 00:05:39,781 --> 00:05:43,471 The title of the region is called Trolls of Transplantation. 110 00:05:43,501 --> 00:05:44,911 So we have team number one. 111 00:05:44,911 --> 00:05:48,061 It's gonna be the very scary BK virus. 112 00:05:48,241 --> 00:05:51,721 And on the other side, I know that Jeannina will call, uh, CMV, 113 00:05:52,021 --> 00:05:54,271 cytomegalovirus, the troll of transplant. 114 00:05:54,301 --> 00:05:59,161 And, um, I think it's really exciting to have these two topics at the intersection 115 00:05:59,161 --> 00:06:03,531 of not only nephrology, but also transplantation, infectious disease. 116 00:06:03,531 --> 00:06:07,281 And I think they really highlight how multidisciplinary and very 117 00:06:07,281 --> 00:06:09,771 complicated transplant patients can be. 118 00:06:10,195 --> 00:06:13,251 So before we get into the specifics, just a quick overview. 119 00:06:13,301 --> 00:06:18,181 BK is a polyoma virus that lies dormant, sleeping in the kidney. 120 00:06:18,181 --> 00:06:22,481 Can cause graft damage, when it's, uh, basically reactivated and 121 00:06:22,481 --> 00:06:26,291 really in very important cause of allograft loss in a high number of 122 00:06:26,291 --> 00:06:28,301 our kidney transplant recipients. 123 00:06:28,611 --> 00:06:33,166 Whereas CMV cytomegalovirus, which I recently learned as part of this is herpes 124 00:06:33,166 --> 00:06:37,666 virus number five, um, that we can ask Jeannina why we never call it by its other 125 00:06:37,666 --> 00:06:42,736 name, um, is the most common opportunistic infection in kidney transplantation. 126 00:06:42,736 --> 00:06:47,456 And of course has serious, both systemic and kidney allograft consequences. 127 00:06:47,546 --> 00:06:50,643 And so today we're gonna kind of unpack, uh, why these two uh, viral 128 00:06:50,643 --> 00:06:53,133 bench warmers have become so dominant. 129 00:06:53,366 --> 00:06:57,476 What makes them, uh, so important and of course why they're gonna, one of them I 130 00:06:57,476 --> 00:06:58,856 hope is gonna win the whole tournament. 131 00:06:59,864 --> 00:07:00,339 Sara Dong: I love it. 132 00:07:00,369 --> 00:07:00,609 Yeah. 133 00:07:00,609 --> 00:07:04,269 I'm personally biased that I feel like I think about these every day. 134 00:07:04,269 --> 00:07:04,539 So, 135 00:07:06,549 --> 00:07:07,479 um, all right. 136 00:07:07,479 --> 00:07:11,099 Well I am gonna hand it over to Hari and Caitlyn to walk us through 137 00:07:11,099 --> 00:07:14,459 some of the background and then up and coming things as we think 138 00:07:14,459 --> 00:07:16,199 about CMV and BK in transplant. 139 00:07:16,674 --> 00:07:17,454 Caitlyn Vlasschaert: Sure, thanks. 140 00:07:17,454 --> 00:07:18,534 So I can get us started. 141 00:07:18,954 --> 00:07:23,424 I think it's probably important before we get into how we sort of monitor and 142 00:07:23,428 --> 00:07:26,788 treat these viruses to talk a little bit about the biology because they're 143 00:07:26,788 --> 00:07:30,868 quite different, the two viruses, and how we specifically, how we treat 144 00:07:30,868 --> 00:07:35,398 them, I think really, relies on our understanding of what they are and, 145 00:07:35,467 --> 00:07:36,751 kind of the specifics about them. 146 00:07:36,751 --> 00:07:40,711 So BK, as Dr. Farouk mentioned, is a small polyomavirus. 147 00:07:40,711 --> 00:07:42,091 It's about five kilobases. 148 00:07:42,091 --> 00:07:42,841 So really small. 149 00:07:42,841 --> 00:07:46,831 It only really encodes, uh, not much, uh, just sort of the viral capsid 150 00:07:46,831 --> 00:07:49,126 protein and not much that we can target. 151 00:07:49,126 --> 00:07:52,051 So when we talk about treatment, we'll see how a lot of what we do 152 00:07:52,051 --> 00:07:55,291 is really just trying to allow our immune system to handle it, but 153 00:07:55,291 --> 00:07:59,501 there's not much in terms of kinases, polymerases that we can target. 154 00:07:59,501 --> 00:08:03,781 It, it hijacks our host immune machinery to be able to 155 00:08:03,861 --> 00:08:05,991 replicate and become problematic. 156 00:08:05,991 --> 00:08:10,311 And so it, lives in the uroepithelial cells and tubular 157 00:08:10,311 --> 00:08:11,781 epithelial cells of the kidney. 158 00:08:11,811 --> 00:08:16,261 And when it becomes activated, that viral replication causes issues 159 00:08:16,261 --> 00:08:20,148 directly locally to the kidney causing kidney damage that we end up seeing 160 00:08:20,343 --> 00:08:21,918 manifest, uh, if we don't treat it. 161 00:08:21,918 --> 00:08:24,678 So it's quite different, as I mentioned from CMV and maybe 162 00:08:24,678 --> 00:08:26,598 Hari can give us a bit about CMV. 163 00:08:27,518 --> 00:08:27,968 Hariharasudan Natarajan: Of course. 164 00:08:27,968 --> 00:08:35,388 So, compared to BK, CMV is the large DNA virus, and in fact, in the herpes 165 00:08:35,388 --> 00:08:37,458 family it has the largest genome. 166 00:08:37,878 --> 00:08:41,648 And with this genome, it also expresses a lot of protein. 167 00:08:42,031 --> 00:08:46,971 The most important of which is the polymerase enzyme and the kinase, 168 00:08:47,271 --> 00:08:52,431 meaning that we have targets to, uh, use pharmacological therapy for. 169 00:08:52,711 --> 00:08:56,741 So unlike BK, along with immunosuppression, we also 170 00:08:56,741 --> 00:09:01,031 have medications that we can use to target these proteins. 171 00:09:01,421 --> 00:09:04,961 Unlike BK which goes and hides in the urothelial cells. 172 00:09:05,246 --> 00:09:08,966 CMV hides within the hematopoietic progenitor cells. 173 00:09:09,176 --> 00:09:14,486 So when it reactivates, it's a systemic disease, it can affect any organ, 174 00:09:14,906 --> 00:09:19,706 including the kidneys, and hence has a very high mortality and morbidity. 175 00:09:19,824 --> 00:09:21,948 Samira Farouk: Jeannina, anything you wanted to add to that? 176 00:09:22,215 --> 00:09:25,375 Jeannina Smith: I think that it's really important to consider, uh, Sara knows 177 00:09:25,595 --> 00:09:30,990 the, the 2026 is supposed to be the year of the host where we consider the host 178 00:09:30,990 --> 00:09:34,830 pathogen interaction, and I love that both of you mentioned the importance of 179 00:09:34,830 --> 00:09:36,750 considering the host's immune response. 180 00:09:37,010 --> 00:09:41,510 I would actually argue that modification or reduction of immunosuppression is 181 00:09:41,510 --> 00:09:43,310 the cornerstone of therapy for both. 182 00:09:43,550 --> 00:09:46,960 Although it's shares it's position at the top with the 183 00:09:46,960 --> 00:09:48,670 antivirals, in the case of CMV. 184 00:09:49,026 --> 00:09:52,361 Caitlyn Vlasschaert: Okay, so maybe we can next move on to how we screen or 185 00:09:52,361 --> 00:09:56,411 watch for the emergence of these viruses in our kidney transplant recipients. 186 00:09:56,411 --> 00:09:58,751 So, starting with BK first. 187 00:09:58,851 --> 00:10:00,981 Usually as mentioned, it's something that a lot of people 188 00:10:00,981 --> 00:10:02,511 just carry without knowing it. 189 00:10:02,511 --> 00:10:06,801 And your native immune system can survey for them and, and keep it under check. 190 00:10:06,801 --> 00:10:10,851 But in the setting of transplant, we don't really screen to see who has 191 00:10:11,041 --> 00:10:13,771 what BK serotype, uh, at baseline. 192 00:10:13,771 --> 00:10:15,881 We just usually screen everyone. 193 00:10:15,881 --> 00:10:20,561 And so for, I think the protocols can vary center to center, but in general, you're 194 00:10:20,561 --> 00:10:24,251 screening for DNA of BK in the serum. 195 00:10:24,391 --> 00:10:27,491 Usually on a monthly basis, for the first while. 196 00:10:27,491 --> 00:10:30,881 And then, uh, every three months we're usually about the first two years. 197 00:10:30,881 --> 00:10:33,281 But again, I think center to center variability. 198 00:10:34,031 --> 00:10:38,431 Then after the first two year period, and even within that first two year period, 199 00:10:38,431 --> 00:10:42,901 but especially after you're watching for, um, needing to test for cause. 200 00:10:42,901 --> 00:10:45,691 So if someone has an AKI [acute kidney injury], if you've recently treated 201 00:10:45,691 --> 00:10:48,451 for rejection or if you've recently increased immunosuppression, there 202 00:10:48,451 --> 00:10:51,841 are certain cases where you may wanna retest for BK to make sure that that's 203 00:10:51,841 --> 00:10:57,151 not at play either contributing to worsening graft function or kind of 204 00:10:57,811 --> 00:11:01,171 in the process of reemerging in the setting of decreased immunosuppression. 205 00:11:01,441 --> 00:11:04,801 And there's a lot of cases where you're personalizing when and if you're 206 00:11:04,801 --> 00:11:06,301 gonna be screening for it as well. 207 00:11:06,527 --> 00:11:08,627 So what do you do when you find BK? 208 00:11:08,687 --> 00:11:11,927 It, it, again, center to center, some variability, but depending 209 00:11:11,927 --> 00:11:13,667 on the viral load to some extent. 210 00:11:14,077 --> 00:11:17,377 In general, if it's less than 10,000, we might repeat it to see if it's 211 00:11:17,377 --> 00:11:19,402 persistent a week or two later. 212 00:11:19,502 --> 00:11:22,477 But again, the focus should be on finding it and confirming 213 00:11:22,477 --> 00:11:24,127 that it's truly there early. 214 00:11:24,547 --> 00:11:29,152 Um, if it's above 10,000, that's fairly diagnostic of BK associated 215 00:11:29,152 --> 00:11:30,712 nephropathy or very high risk. 216 00:11:30,712 --> 00:11:34,812 And so in both cases we will we'll discuss the first step 217 00:11:34,812 --> 00:11:36,312 is to reduce immunosuppression. 218 00:11:36,312 --> 00:11:40,152 So the degree to which or what you'll do, depends to some extent 219 00:11:40,152 --> 00:11:44,362 how severe you think the BK viremia is, and if you think there's already 220 00:11:44,362 --> 00:11:46,432 some associated graft dysfunction. 221 00:11:46,742 --> 00:11:49,852 And there's been various strategies, uh, discussed including 222 00:11:49,852 --> 00:11:53,452 whether you do anti metabolite reduction or CNI reduction first. 223 00:11:53,452 --> 00:11:56,782 So I think it'll be great to hear about what some of the experts do 224 00:11:56,782 --> 00:11:58,372 in practice or what they've seen. 225 00:11:58,612 --> 00:12:01,732 Um, and then just important to mention, I think that in certain 226 00:12:01,732 --> 00:12:07,802 cases, biopsy is warranted and so especially, if there's an AKI, often in 227 00:12:07,802 --> 00:12:09,782 children, they'll do biopsies as well. 228 00:12:10,397 --> 00:12:14,237 And then especially if it's a case where the individual is considered higher 229 00:12:14,237 --> 00:12:19,017 immunological risks, so if they've had prior rejection or a recent DSA 230 00:12:19,047 --> 00:12:23,517 positive, you may want to do, um, a biopsy because the risk of reducing 231 00:12:23,517 --> 00:12:24,927 immunosuppression may be greater. 232 00:12:24,977 --> 00:12:26,837 And then of course there's a lot of clinical judgment that 233 00:12:26,867 --> 00:12:29,877 comes into how exactly you're, you're managing all of this. 234 00:12:30,972 --> 00:12:31,842 Samira Farouk: Yeah, I'll just add to that. 235 00:12:31,842 --> 00:12:32,602 Thanks, Caitlyn. 236 00:12:32,632 --> 00:12:35,332 I think the screening can be very tough, uh, particularly when 237 00:12:35,332 --> 00:12:36,802 you get out from the first year. 238 00:12:36,802 --> 00:12:39,852 I think most transplant centers like, uh, we do at ours. 239 00:12:40,132 --> 00:12:43,942 We're screening for BK virus every month and everything is protocolized. 240 00:12:44,002 --> 00:12:47,342 When the patient leaves the hospital, those tests are in and basically, 241 00:12:47,492 --> 00:12:48,872 you have a plan for 12 months. 242 00:12:49,142 --> 00:12:52,406 I think what happens after that, it becomes a little bit more nebulous. 243 00:12:52,406 --> 00:12:54,356 And I think we all have different approaches. 244 00:12:54,717 --> 00:12:58,287 I feel like I modify mine a bit, uh, based on the person in front 245 00:12:58,287 --> 00:13:01,817 of me, but I think I try to check it at least, once a year if I can. 246 00:13:02,107 --> 00:13:05,917 And I think something that makes a BK so challenging is that is the completely 247 00:13:05,917 --> 00:13:08,887 asymptomatic nature, not to kind of jump ahead to, you know, voting on 248 00:13:08,887 --> 00:13:12,734 the bracket, but, but it's really silent and, you could just check it 249 00:13:12,734 --> 00:13:16,654 randomly and find a very high number that you're surprised by because we 250 00:13:16,654 --> 00:13:18,934 have not great ways to, to predict it. 251 00:13:19,184 --> 00:13:22,844 And then, um, as you were kind of alluding to with when we do a biopsy or 252 00:13:22,844 --> 00:13:28,381 not, the treatment is, is tough without any, uh, for now targeted antivirals. 253 00:13:28,591 --> 00:13:30,961 Um, who can you lower immunosuppression on or not. 254 00:13:31,071 --> 00:13:35,121 And we have new tools now, like, donor derived cell-free DNA, that can help 255 00:13:35,301 --> 00:13:39,951 guide us a little bit more, um, as a non-invasive biomarker that can tell 256 00:13:39,951 --> 00:13:44,901 us not specifically about the presence of rejection, but about kidney injury. 257 00:13:45,171 --> 00:13:48,511 And so in most of the time when we talk about donor derived, 258 00:13:48,531 --> 00:13:52,881 cell-free, DNA, we're talking about screening for subclinical rejection. 259 00:13:53,101 --> 00:13:58,051 However, if somebody has BK nephropathy, they can also have release of that DNA. 260 00:13:58,051 --> 00:14:00,241 It's, it's still injury to the kidney cells. 261 00:14:00,511 --> 00:14:03,591 Um, but, if you're lowering immunosuppression, that might 262 00:14:03,591 --> 00:14:07,541 be one way to, to look for the potential development of a rejection. 263 00:14:07,551 --> 00:14:09,861 So the screening, I think, again, the take homes are that 264 00:14:09,861 --> 00:14:12,111 there's no really, uh, rules. 265 00:14:12,171 --> 00:14:16,041 Um, once we get past the first year, you can have it any time. 266 00:14:16,291 --> 00:14:19,771 You know, we have a mnemonic that we use for AKI of the kidney 267 00:14:19,771 --> 00:14:25,141 transplant "CRAB" and the B stands for BK and other viruses like CMV. 268 00:14:25,141 --> 00:14:27,331 So BK, again, taking a stand. 269 00:14:28,556 --> 00:14:28,766 Jeannina Smith: Yeah. 270 00:14:28,796 --> 00:14:35,066 And when we talk about prevention of CMV infection, um, I think it's most 271 00:14:35,066 --> 00:14:41,166 helpful when we think of CMV as a problem of the lack of educated T cells or the 272 00:14:41,166 --> 00:14:43,086 lack of the activity of those T cells. 273 00:14:43,536 --> 00:14:46,746 And so, I think understanding that concept means that we don't have to 274 00:14:46,746 --> 00:14:52,146 memorize all R this, D that , but instead to say, does the person have 275 00:14:52,146 --> 00:14:55,326 preformed T cell immunity to CMV? 276 00:14:55,696 --> 00:14:59,476 And if so, what are we doing to put a boot on the neck of those T cells? 277 00:15:00,016 --> 00:15:03,016 So, I think when you think about it that way, it's really helpful. 278 00:15:03,176 --> 00:15:09,536 And so we do know that if you don't treat with antivirals and someone has CMV. 279 00:15:09,806 --> 00:15:12,716 If they're donor positive, recipient positive, if they've had the virus 280 00:15:12,716 --> 00:15:15,926 in their body, that they have an extremely high incidence of 281 00:15:15,926 --> 00:15:20,126 developing viremia, meaning you can detect the virus in their blood. 282 00:15:20,456 --> 00:15:24,326 And actually further, they have an extremely high risk of developing 283 00:15:24,566 --> 00:15:28,226 CMV disease, either CMV syndrome, where they feel sick, they feel 284 00:15:28,226 --> 00:15:31,206 virally, they have fevers and aches. 285 00:15:31,476 --> 00:15:34,236 Um, and during that they may have some transaminitis and 286 00:15:34,236 --> 00:15:38,166 some cell count problems, or CMV disease where they actually have 287 00:15:38,166 --> 00:15:39,726 infiltration of their tissues. 288 00:15:40,026 --> 00:15:42,666 And in kidney transplant recipients, that's most likely 289 00:15:42,666 --> 00:15:43,836 gonna be in the GI tract. 290 00:15:44,541 --> 00:15:47,391 Um, and so we know that we have to do something to prevent that. 291 00:15:47,391 --> 00:15:52,901 And prior to, the drugs that we have available now, um, this was a horrible and 292 00:15:52,901 --> 00:15:55,361 hideous and deadly troll of transplant. 293 00:15:55,821 --> 00:16:01,491 But when we developed drugs to help us and protocols to help us, um, manage 294 00:16:01,491 --> 00:16:06,061 this infection using antivirals, the troll shrunk and became more manageable, 295 00:16:06,271 --> 00:16:07,621 but it's still under the bridge. 296 00:16:07,981 --> 00:16:12,741 So if you ask me my opinions about CMV prevention, I would 297 00:16:12,741 --> 00:16:14,421 say that it's evolved over time. 298 00:16:14,631 --> 00:16:18,501 And so, I'm an ID doctor and I like to quash those viruses, and I don't 299 00:16:18,501 --> 00:16:20,361 like the idea of chronic inflammation. 300 00:16:20,631 --> 00:16:24,651 And so 10 years ago, I would've told you, without a doubt, use our 301 00:16:24,651 --> 00:16:30,451 best drug and use it hard and help prevent that virus from waking up and 302 00:16:30,451 --> 00:16:32,961 coming out of the cave of latency. 303 00:16:33,381 --> 00:16:36,321 I think that I've evolved and become softer with time towards 304 00:16:36,321 --> 00:16:40,581 the virus as I understand the importance of the immune response. 305 00:16:41,061 --> 00:16:46,101 And so what we've seen is that especially when someone has no preformed immunity 306 00:16:46,101 --> 00:16:52,996 to CMV, giving them a little taste, um, allows them to educate their T cells 307 00:16:53,181 --> 00:16:54,831 and have some protection down the road. 308 00:16:55,131 --> 00:16:58,851 So in the old days when I crushed that virus and made sure that there was no 309 00:16:58,851 --> 00:17:02,961 recurrence, at some point it's like, while we're talking about games, the game of 310 00:17:02,961 --> 00:17:07,221 kick the can because, um, we knew patients couldn't stand antivirals forever. 311 00:17:07,221 --> 00:17:10,491 It was too toxic and too expensive and too difficult. 312 00:17:10,741 --> 00:17:15,691 And so what we found is that they would delay CMV but not infinitely. 313 00:17:15,751 --> 00:17:18,271 As soon as you came off antivirals, there was a high risk 314 00:17:18,271 --> 00:17:20,341 of post prophylaxis infection. 315 00:17:20,746 --> 00:17:25,516 And what we're seeing is with some of the other preventative measures, so 316 00:17:25,696 --> 00:17:30,316 universal prophylaxis can either be done nowadays with, uh, ganciclovir product, 317 00:17:30,316 --> 00:17:33,496 usually valganciclovir or with letermovir. 318 00:17:33,826 --> 00:17:36,076 Um, and there's preemptive monitoring. 319 00:17:36,076 --> 00:17:40,966 And what that is is checking CMV frequently because we know that 320 00:17:40,966 --> 00:17:43,876 viremia precedes clinical disease. 321 00:17:44,476 --> 00:17:49,216 So as it turns out, we first got a whiff from liver transplant patients that the 322 00:17:49,216 --> 00:17:53,926 patients may do better overall if you allow them to develop some CMV specific 323 00:17:53,926 --> 00:17:56,236 immunity by using preemptive therapy. 324 00:17:56,596 --> 00:18:01,816 And interestingly, um, I was also maybe a bit of a naysayer about letermovir 325 00:18:01,966 --> 00:18:06,046 because it doesn't crush that virus the way that I like to crush the virus. 326 00:18:06,286 --> 00:18:11,236 Um, we often have low levels of CMV viremia, a little bit of breakthrough. 327 00:18:11,506 --> 00:18:13,846 And at first I thought that was a terrible, terrible idea. 328 00:18:14,191 --> 00:18:18,721 But as it turns out, it gives our immune system a little shot at the virus. 329 00:18:18,791 --> 00:18:23,661 And so we are seeing better development of T-cell specific immunity in that group. 330 00:18:23,931 --> 00:18:26,571 Um, and there's some other advantages that we can talk about later. 331 00:18:26,851 --> 00:18:31,041 But those are some ways that I can think about and approach how I prevent 332 00:18:31,041 --> 00:18:33,201 CMV in my transplant recipients. 333 00:18:34,047 --> 00:18:36,147 Samira Farouk: I have a, a little bit of a naive question. 334 00:18:36,247 --> 00:18:40,987 So we know that for both BK and CMV, you know, the majority of adult population 335 00:18:40,987 --> 00:18:43,357 has been exposed and were seropositive. 336 00:18:43,567 --> 00:18:49,357 So for CMV, is it because immunocompetent people are not becoming viremic, that they 337 00:18:49,357 --> 00:18:53,927 don't have any sort of T-cell response or how, how can there be IgG but... 338 00:18:54,001 --> 00:18:56,911 Jeannina Smith: So, yeah, so I, it's not quite the same. 339 00:18:56,911 --> 00:19:01,701 So almost everybody has BK and JC virus, and we know that though it 340 00:19:01,701 --> 00:19:05,521 says in the nineties, it's the high nineties by the time of adulthood, 341 00:19:05,701 --> 00:19:07,231 people have had this virus. 342 00:19:07,511 --> 00:19:13,751 CMV, like most of the herpes viruses, has to do with our human human interaction. 343 00:19:13,961 --> 00:19:18,111 So there is no other place to get the human herpes viruses. 344 00:19:18,111 --> 00:19:21,531 Those are from close contact with other human beings. 345 00:19:21,811 --> 00:19:25,351 And so it does have some correlation with risk behavior, and I think this 346 00:19:25,351 --> 00:19:30,541 is something many of my recipients find very interesting in that, um, 347 00:19:30,571 --> 00:19:36,811 a transplant recipient or potential recipient has a much lower risk of having 348 00:19:36,811 --> 00:19:40,591 had prior CMV than does an organ donor. 349 00:19:40,906 --> 00:19:44,026 And some of this has to do with comfort with risk behavior. 350 00:19:44,296 --> 00:19:49,396 So our recipients may have been chronically ill and careful and 351 00:19:49,396 --> 00:19:53,486 avoiding contact in the ways that we get human herpes viruses, so 352 00:19:53,486 --> 00:19:55,046 close contact with bodily fluids. 353 00:19:55,346 --> 00:20:00,396 Um, whereas our donors may be more comfortable with risks in life, that 354 00:20:00,396 --> 00:20:04,736 may lead them to be more likely to be organ donors, but it also may lead 355 00:20:04,736 --> 00:20:06,746 them to have more human herpes viruses. 356 00:20:06,986 --> 00:20:11,716 So we do know that donors have a much higher rate of positivity. 357 00:20:11,926 --> 00:20:13,576 So I think that's one of the reasons. 358 00:20:13,576 --> 00:20:17,516 Certainly we know that there are different serovars and that, for example, an 359 00:20:17,516 --> 00:20:21,866 organ recipient may have some preformed immunity and still get a different 360 00:20:21,981 --> 00:20:24,576 CMV and still may get acutely ill. 361 00:20:24,786 --> 00:20:25,986 Or it may be more. 362 00:20:25,986 --> 00:20:30,636 And I think this is what I think is that our T-cell immune suppression is 363 00:20:30,666 --> 00:20:35,536 powerful enough that we're not allowing that preformed immunity to come back. 364 00:20:35,746 --> 00:20:39,136 But those are the patients I worry a little bit less about in the long run. 365 00:20:39,316 --> 00:20:43,336 So again, once we've taken our boot off its neck and it's not quite 366 00:20:43,336 --> 00:20:47,806 holding down that those T cells quite as strongly that person's preformed 367 00:20:47,806 --> 00:20:49,636 immunity can come back and help. 368 00:20:49,936 --> 00:20:54,936 But those that had never made immunity in the first place, there's these gentle 369 00:20:54,936 --> 00:20:59,226 baby steps of showing it CMV, but not letting CMV absolutely clobber them. 370 00:20:59,496 --> 00:21:01,716 Um, seems like it's gonna be helpful. 371 00:21:02,767 --> 00:21:05,052 Samira Farouk: Wow, that is a really fascinating, that was not 372 00:21:05,052 --> 00:21:06,707 the answer I was, uh, expecting. 373 00:21:08,047 --> 00:21:12,237 Um, Hari, thinking about what we discussed so far about CMV, anything 374 00:21:12,237 --> 00:21:15,297 that was particularly interesting as you were learning about this section, 375 00:21:15,297 --> 00:21:17,857 as you prepared the scouting report. 376 00:21:18,374 --> 00:21:21,544 Hariharasudan Natarajan: So as I was preparing this section, one thing 377 00:21:21,544 --> 00:21:26,019 that was new to me was the preemptive approach because at our center, 378 00:21:26,049 --> 00:21:28,809 we, uh, do universal prophylaxis. 379 00:21:29,139 --> 00:21:33,344 And, as Dr. Smith was mentioning, one thing that is striking was like 380 00:21:33,344 --> 00:21:38,764 allowing the body to be exposed to the CMV virus and antigen to 381 00:21:38,794 --> 00:21:40,624 build his own immune response. 382 00:21:40,954 --> 00:21:44,764 That is completely shut down by using valganciclovir. 383 00:21:45,154 --> 00:21:49,744 And I was just wondering what the downside would be of using preemptive therapy. 384 00:21:49,744 --> 00:21:54,104 And then I realized that like, you know, weekly screening, uh, timely 385 00:21:54,124 --> 00:21:57,874 following up of resource and like, you know, initiating the treatment at the 386 00:21:57,874 --> 00:21:59,944 right time, these might be challenging. 387 00:22:00,214 --> 00:22:03,784 So I think it's just very institution dependent if you have the resources 388 00:22:03,844 --> 00:22:07,384 available, I think preemptive treatment will be a very good option as well. 389 00:22:07,919 --> 00:22:10,379 Samira Farouk: Do we know if there's a, has anyone ever asked patients 390 00:22:10,379 --> 00:22:14,339 what they, what they prefer, from just patient quality of life standpoint, 391 00:22:14,339 --> 00:22:15,899 preemptive versus a universal? 392 00:22:16,333 --> 00:22:18,433 Jeannina Smith: I mean, I certainly think there are some patients that 393 00:22:18,433 --> 00:22:20,113 hate taking medicine every day. 394 00:22:20,393 --> 00:22:25,113 I think that some of this has to do with the population and how spread out it is. 395 00:22:25,143 --> 00:22:28,653 Um, I come from the University of Wisconsin where we are one of the 396 00:22:28,653 --> 00:22:32,158 largest transplant centers in the country, and we have a catchment, not 397 00:22:32,158 --> 00:22:35,908 only all over the country, but all over the world, including some of the 398 00:22:35,908 --> 00:22:38,068 pretty rural areas of the Midwest. 399 00:22:38,368 --> 00:22:44,368 So I find that I would worry very much about the ability to get a lab reliably. 400 00:22:44,418 --> 00:22:48,858 We have lots of snowstorms and difficulties get a lab reliably that I 401 00:22:48,858 --> 00:22:54,798 need to respond to because the danger, and it is not a small one, is if a patient 402 00:22:54,798 --> 00:23:01,688 is lost to follow up that viral load can sometimes shoot through the roof and you 403 00:23:01,688 --> 00:23:04,108 need to be able to respond to it nimbly. 404 00:23:04,708 --> 00:23:08,518 And if you're not able, um, one of my colleagues who was the medical 405 00:23:08,518 --> 00:23:11,908 director of transplant infectious disease at Northwestern, I always 406 00:23:11,908 --> 00:23:14,818 felt he was very spoiled because in many cases that's a big city. 407 00:23:14,818 --> 00:23:18,628 He might have the similar number of patients, but they were all within a much 408 00:23:18,628 --> 00:23:21,808 more tight area, um, to the hospital. 409 00:23:21,838 --> 00:23:25,708 So they were able to get away with things so that I couldn't, when half my patients 410 00:23:25,708 --> 00:23:28,018 were in rural areas of the Midwest. 411 00:23:29,054 --> 00:23:33,674 Sara Dong: Yeah, and I can share, we have a nice graphic, there's a chart in the 412 00:23:33,674 --> 00:23:38,504 AST ID Community of Practice guidelines that has the like compare and contrast. 413 00:23:38,744 --> 00:23:42,764 Hari, like you were mentioning, of prophylaxis versus preemptive therapy. 414 00:23:42,764 --> 00:23:47,654 And I think the other thing to just say is I don't think it's always black and white. 415 00:23:47,654 --> 00:23:49,664 I think a lot of centers have a hybrid approach 416 00:23:49,718 --> 00:23:50,048 Jeannina Smith: Mm-hmm. 417 00:23:50,474 --> 00:23:52,844 Sara Dong: where they do have someone on prophylaxis for whichever 418 00:23:53,084 --> 00:23:58,264 agreed upon period of time, probably based on their sero status risk. 419 00:23:58,514 --> 00:24:02,264 And then have some sort of preemptive monitoring after that. 420 00:24:02,654 --> 00:24:07,694 And so I think, just like you said, comparing, you know, for that individual 421 00:24:07,694 --> 00:24:09,554 patient, what's gonna be harder? 422 00:24:09,554 --> 00:24:13,094 Is it gonna be getting those labs or, um, is it an issue with 423 00:24:13,094 --> 00:24:15,044 toxicities from the meds and so on. 424 00:24:15,999 --> 00:24:18,299 Samira Farouk: I went to a really fascinating, a few American 425 00:24:18,299 --> 00:24:19,499 transplant congresses ago. 426 00:24:19,499 --> 00:24:23,219 They had a whole debate, I think it was an hour, just about this topic. 427 00:24:23,249 --> 00:24:27,449 And maybe for next Neph Madness, I can get them to give CMV an entire region 428 00:24:27,509 --> 00:24:29,759 and then we can just do more of this. 429 00:24:33,029 --> 00:24:33,509 Um, all 430 00:24:33,548 --> 00:24:33,608 Jeannina Smith: You. 431 00:24:33,669 --> 00:24:38,489 Samira Farouk: Alright BK has been lying, BK has been lying dormant. 432 00:24:38,519 --> 00:24:45,109 Uh, so Caitlyn, tell us about why BK has no, uh, really enemies right now 433 00:24:45,109 --> 00:24:47,089 and no antivirals that have worked. 434 00:24:47,866 --> 00:24:50,836 Caitlyn Vlasschaert: Yeah, I think it's just strategically very, very 435 00:24:50,836 --> 00:24:54,826 small and it doesn't have really any targets on its surface or any viral 436 00:24:54,826 --> 00:24:56,566 proteins that it uses to replicate. 437 00:24:56,566 --> 00:25:01,466 So as some of the agents that we've talked about for CMV, they target some of the 438 00:25:01,466 --> 00:25:05,576 polymerases, the kinases, whereas BK, they're starting to develop monoclonal 439 00:25:05,576 --> 00:25:09,056 antibodies from what I understand, to the sole viral capsid protein. 440 00:25:09,056 --> 00:25:11,636 But there's not much else that can actually be targeted. 441 00:25:11,636 --> 00:25:14,546 So other than boosting t-cell immunity through reducing 442 00:25:14,546 --> 00:25:17,556 some of the immunosuppression, there's not much that we can do. 443 00:25:17,656 --> 00:25:23,056 I will say that in some of the future, uh, kind of therapy section that we cover. 444 00:25:23,476 --> 00:25:27,856 There's some exciting, I think, new data on specifically posoleucel, which 445 00:25:27,856 --> 00:25:35,206 is, uh, giving patients off the shelf T-cells that target not only, uh, BK but 446 00:25:35,236 --> 00:25:38,366 also five other viruses including CMV. 447 00:25:38,366 --> 00:25:41,006 And so I was wondering, I don't have any practical experience with this. 448 00:25:41,036 --> 00:25:44,336 I was just wondering where we're at with that clinically and do we see 449 00:25:44,336 --> 00:25:49,106 this being a promising future therapy that, you know, in five, 10 years 450 00:25:50,186 --> 00:25:51,386 that a lot of people will be on? 451 00:25:51,386 --> 00:25:52,886 Or where do we see this going? 452 00:25:52,886 --> 00:25:55,716 I guess I'd like to hear from what a lot of the experts think on this. 453 00:25:56,606 --> 00:25:59,276 Jeannina Smith: Yeah, I think it's a challenge because those, 454 00:25:59,276 --> 00:26:00,656 they have short half lives. 455 00:26:00,656 --> 00:26:02,576 They have to be used pretty much right away. 456 00:26:02,576 --> 00:26:06,176 When I first heard about this, I was very, very concerned to be honest 457 00:26:06,176 --> 00:26:07,616 about graft versus host disease. 458 00:26:07,946 --> 00:26:11,396 'cause the other part, uh, other hat I wear is not just solid organ 459 00:26:11,396 --> 00:26:13,856 transplant, but liquid transplant as well. 460 00:26:13,856 --> 00:26:16,976 And, and that's certainly a devastating complication that I have 461 00:26:16,976 --> 00:26:18,776 seen with solid organ transplant. 462 00:26:18,926 --> 00:26:22,706 But thank goodness, not very often compared to the other patient 463 00:26:23,096 --> 00:26:24,716 population that I care for. 464 00:26:25,106 --> 00:26:30,386 And so I was assured that these cells don't persist or replicate in the body. 465 00:26:30,566 --> 00:26:33,506 That made me feel better in terms of risk for development 466 00:26:33,506 --> 00:26:34,706 of graft versus host disease. 467 00:26:35,036 --> 00:26:38,336 But it also makes you feel worse when you realize they won't last a long time. 468 00:26:38,336 --> 00:26:41,756 So they work in the very short run, at least the current iterations. 469 00:26:42,026 --> 00:26:46,446 Um, but they won't, um, be a good solution over time, because they would 470 00:26:46,446 --> 00:26:50,096 require frequent infusion of the cells. 471 00:26:50,366 --> 00:26:54,596 Um, we had a protocol, and I have used this for patients when we 472 00:26:54,596 --> 00:26:56,936 had severe and refractory CMV. 473 00:26:57,266 --> 00:27:01,946 And I have to say that, um, I wanna give a shout out to another 474 00:27:01,946 --> 00:27:06,626 MVP of the team, which is our transplant and ID pharmacists. 475 00:27:07,046 --> 00:27:11,736 So at University of Wisconsin, we have the first in the world, an antiviral 476 00:27:11,736 --> 00:27:16,566 stewardship service that assists our solid organ transplant programs and they 477 00:27:16,566 --> 00:27:22,576 assess the immunosuppression, the CMV status, the CMV medications, and then 478 00:27:22,696 --> 00:27:27,326 if there's breakthrough viremia, assists the transplant teams in modification 479 00:27:27,326 --> 00:27:31,076 of immune suppression as well as antiviral selection and monitoring. 480 00:27:31,496 --> 00:27:36,926 And so we are for sure the spoiled brats as clinicians and our patients 481 00:27:37,046 --> 00:27:40,796 have done tremendously wonderful since the institution of this service. 482 00:27:41,066 --> 00:27:46,806 So thank goodness we went from having multiple patients who experienced what 483 00:27:46,806 --> 00:27:50,536 I think is the, the real tragedy in CMV, which is drug resistance, with 484 00:27:50,566 --> 00:27:55,196 ganciclovir resistant severe disease, to having almost none every year. 485 00:27:55,406 --> 00:28:00,266 Um, and I going to give a lot of the credit to those MVP colleagues. 486 00:28:00,566 --> 00:28:04,976 Um, so I, as we've moved to having some new agents in the 487 00:28:04,976 --> 00:28:11,206 armamentarium, I feel less inclined to think that the T-cell infusion 488 00:28:11,206 --> 00:28:12,946 is gonna be the long-term solution. 489 00:28:12,946 --> 00:28:17,266 I think it's still gonna be reserved for really severe cases, but, I think 490 00:28:17,266 --> 00:28:21,556 we've learned a lot about CMV and how it interacts with the immune system. 491 00:28:21,616 --> 00:28:27,746 And I think that with our current drugs that are available, it will continue to 492 00:28:27,746 --> 00:28:32,426 be like, not something that every patient gets but used only in special cases. 493 00:28:32,636 --> 00:28:33,506 Sara, what do you think? 494 00:28:34,237 --> 00:28:36,762 Sara Dong: Yeah, I've only used it in those settings for 495 00:28:36,762 --> 00:28:39,372 refractory stem cell cases. 496 00:28:39,372 --> 00:28:42,122 I don't actually think , I've necessarily had one for a 497 00:28:42,812 --> 00:28:44,312 solid organ transplant patient. 498 00:28:44,702 --> 00:28:47,422 But yeah, I have nothing additional to add. 499 00:28:47,422 --> 00:28:51,592 I, the only thing I was gonna say is I was muted, but I had an audible gasp 500 00:28:51,592 --> 00:28:55,552 at the thought of having an antiviral stewardship team, and that sounds amazing. 501 00:28:55,861 --> 00:28:57,451 Jeannina Smith: Yeah, it's pretty great. 502 00:28:57,532 --> 00:28:59,662 Sara Dong: Shout out to all the amazing pharmacists. 503 00:28:59,662 --> 00:29:00,172 They're the best. 504 00:29:00,172 --> 00:29:00,412 So. 505 00:29:03,342 --> 00:29:06,697 Samira Farouk: Um, I have another, uh, maybe, uh, naive question. 506 00:29:06,697 --> 00:29:11,407 So we have six viruses for kind of the price of one with the posoleucel. 507 00:29:11,527 --> 00:29:13,567 What is the reason for that? 508 00:29:13,567 --> 00:29:16,747 Is it because it's easier to train them on six at a time? 509 00:29:16,747 --> 00:29:17,677 Or why? 510 00:29:17,737 --> 00:29:18,847 Why do they do it that way? 511 00:29:18,877 --> 00:29:20,107 Do we, do we know? 512 00:29:20,232 --> 00:29:23,742 Jeannina Smith: Yeah, I mean, I think that, um, I always talk to my 513 00:29:23,742 --> 00:29:27,652 learners, I always say, you know, you gotta look, if you see one sexually 514 00:29:27,652 --> 00:29:31,852 transmitted infection or pregnancy, you get those infections the same way. 515 00:29:31,852 --> 00:29:33,442 So you always have to think about all of them. 516 00:29:33,652 --> 00:29:36,712 And I think, again, when we're really thinking about the host, it's important to 517 00:29:36,712 --> 00:29:41,482 remember that none of these opportunistic infections occur in isolation. 518 00:29:41,482 --> 00:29:45,112 They occur because the host immune response is depressed. 519 00:29:45,442 --> 00:29:48,962 And so, it's long been lore that CMV is associated with 520 00:29:48,962 --> 00:29:50,402 other opportunistic infections. 521 00:29:50,402 --> 00:29:53,012 And our group did show that that is in fact the case. 522 00:29:53,072 --> 00:29:58,052 And so I think it's important to remember that, many of these infections, BK and 523 00:29:58,052 --> 00:30:00,782 CMV especially, are actually markers. 524 00:30:00,932 --> 00:30:04,112 They're markers that the immune response has been depressed. 525 00:30:04,112 --> 00:30:08,222 And so I think that that would be a reason why a more pluripotent, uh, 526 00:30:08,252 --> 00:30:12,032 T-cell would be valuable because you're not just at risk for BK 527 00:30:12,032 --> 00:30:14,042 because of your depressed immunity. 528 00:30:14,042 --> 00:30:18,882 You're not just at risk for CMV, you're at risk for EBV and many 529 00:30:18,882 --> 00:30:23,592 other different infections chronic norovirus , um, other real scourges 530 00:30:23,692 --> 00:30:25,672 for our, our transplant patients. 531 00:30:25,762 --> 00:30:29,092 And so thinking of it in that setting, I always say kind of 532 00:30:29,152 --> 00:30:30,472 considering the whole patient. 533 00:30:30,652 --> 00:30:35,722 Um, I just discovered, so my, my oldest child is about to take his driver's 534 00:30:35,722 --> 00:30:40,558 test that they don't require parallel parking training anymore to pass the 535 00:30:40,558 --> 00:30:42,418 driver's test in Wisconsin at least. 536 00:30:42,808 --> 00:30:48,048 But this, um, is a powerful marker of failure in my life, uh, is 537 00:30:48,048 --> 00:30:49,338 to learn how to parallel park. 538 00:30:49,428 --> 00:30:52,968 I'll still choose not to if I have any choice, but I think of getting 539 00:30:52,968 --> 00:30:56,988 that sweet spot of immunosuppression exactly like parallel parking. 540 00:30:56,988 --> 00:31:01,068 If you do it right, you slide right into that spot and everything's good. 541 00:31:01,278 --> 00:31:03,528 But if you do it wrong, you're hitting the back bumper. 542 00:31:03,528 --> 00:31:04,788 You're hitting the front bumper. 543 00:31:04,968 --> 00:31:07,548 And so I think of the front bumper as rejection. 544 00:31:07,668 --> 00:31:10,878 You have not enough immune suppression and that back bumper 545 00:31:10,878 --> 00:31:12,378 is opportunistic infection. 546 00:31:12,708 --> 00:31:17,688 Um, and so CMV is really hitting the bumper hard, so is BK to tell us that 547 00:31:17,688 --> 00:31:19,518 we've over immunosuppressed that patient. 548 00:31:19,828 --> 00:31:24,028 So I think on occasion it feels like for some of my patients, boy, that that 549 00:31:24,028 --> 00:31:28,138 parking spot is so narrow, it's almost impossible to slide them in without, um, 550 00:31:28,138 --> 00:31:30,208 getting the, uh, bumpers on either side. 551 00:31:31,504 --> 00:31:31,654 Samira Farouk: All right. 552 00:31:31,654 --> 00:31:35,404 Maybe let's move from posoleucel to, uh, therapies that we actually use. 553 00:31:35,404 --> 00:31:39,064 Um, Hari you wanna tell us a little bit about the current state of CMV treatment? 554 00:31:39,338 --> 00:31:39,938 Hariharasudan Natarajan: Of course. 555 00:31:39,938 --> 00:31:43,478 Uh, so before we get to the treatment, I think it's important 556 00:31:43,478 --> 00:31:48,258 to understand the difference between CMV infection and CMV disease. 557 00:31:48,538 --> 00:31:53,848 CME infection is defined as CMV replication, which is identified by 558 00:31:53,848 --> 00:31:57,308 using CMV PCR or antigenemia tests. 559 00:31:57,744 --> 00:32:03,414 CME disease, on the other hand, is CMV replication with associated symptoms. 560 00:32:03,654 --> 00:32:08,904 It could be fever, thrombocytopenia, leukopenia, or it could also 561 00:32:08,904 --> 00:32:10,644 be tissue invasive disease. 562 00:32:10,974 --> 00:32:17,116 And, uh, the treatment of which is determined by how severe the disease is 563 00:32:17,116 --> 00:32:22,891 at presentation, we either have an option to do oral valganciclovir or ganciclovir. 564 00:32:23,276 --> 00:32:26,336 There has been studies showing that the oral treatment is 565 00:32:26,336 --> 00:32:28,136 as good as the IV treatment. 566 00:32:28,141 --> 00:32:32,276 And if I were a patient, I would obviously choose to oral option, but 567 00:32:32,306 --> 00:32:38,306 we still do use IV for severe disease or high CMV viral load at presentation. 568 00:32:39,206 --> 00:32:44,229 So this is our first drawing option, both oral valganciclovir and ganciclovir. 569 00:32:44,534 --> 00:32:49,804 These work after being activated by the kinase on the DNA polymerase. 570 00:32:50,194 --> 00:32:54,514 If the patient continues to have high viral load or rising viral 571 00:32:54,514 --> 00:32:58,984 load or worsening tissue invasive disease after two weeks of treatment, 572 00:32:59,014 --> 00:33:00,964 we call it refractory disease. 573 00:33:01,354 --> 00:33:06,306 And if the refractory disease is associated with resistance, then we 574 00:33:06,306 --> 00:33:08,316 call it as a resistant CMV disease. 575 00:33:08,716 --> 00:33:12,826 And for the treatment of refractory and resistant disease, we have a 576 00:33:12,826 --> 00:33:15,319 new kid on the block, maribavir. 577 00:33:15,439 --> 00:33:21,059 It has been shown to be as effective as foscarnet, which basically, as you 578 00:33:21,059 --> 00:33:23,399 all know, is, uh, very nephrotoxic. 579 00:33:23,399 --> 00:33:28,949 We don't like to use it unless we have to definitely use it, and we still use it in 580 00:33:28,949 --> 00:33:34,989 case of extremely severe disease, in which case we prefer foscarnet over maribavir. 581 00:33:35,526 --> 00:33:40,266 Samira Farouk: And so Jeannina of the, um, new therapies, do you feel they weigh 582 00:33:40,266 --> 00:33:42,821 in compared to what we have already? 583 00:33:43,527 --> 00:33:48,257 Jeannina Smith: So without question, ganciclovir and valganciclovir are still 584 00:33:48,307 --> 00:33:52,427 the GOAT, when it comes to treating these infections, they're extremely potent. 585 00:33:52,784 --> 00:33:56,744 They're extremely effective, but they do have adverse effects. 586 00:33:56,744 --> 00:33:59,724 So I think there's, there's a couple things that I would kind of 587 00:33:59,784 --> 00:34:02,334 reinforce, uh, about those agents. 588 00:34:02,860 --> 00:34:08,740 One is that when you're treating CMV, I just told you earlier that I've gotten 589 00:34:08,800 --> 00:34:14,055 much more comfortable with the idea of giving the patient a whiff of CMV virus. 590 00:34:14,235 --> 00:34:18,175 When you're treating CMV infection or disease, you cannot 591 00:34:18,175 --> 00:34:19,855 show that virus your cards. 592 00:34:20,185 --> 00:34:26,065 You have to be very, very mindful that you are hitting that virus with the 593 00:34:26,065 --> 00:34:31,525 optimum dosing of those agents because the development of ganciclovir resistant 594 00:34:31,525 --> 00:34:35,175 CMV is challenging in the best case. 595 00:34:35,475 --> 00:34:40,985 So, one of the things that we encounter is people adjusting, um, too aggressively 596 00:34:40,985 --> 00:34:43,295 down because of variable renal function. 597 00:34:43,622 --> 00:34:44,762 I don't advocate for that. 598 00:34:45,032 --> 00:34:49,142 I don't advocate for adjusting down your dose because you have cytopenias. 599 00:34:49,142 --> 00:34:50,282 So you may get cytopenias. 600 00:34:50,282 --> 00:34:53,717 They actually may reverse with treatment with ganciclovir because 601 00:34:53,717 --> 00:34:55,427 they're caused actually by the virus. 602 00:34:55,637 --> 00:34:58,787 But the last thing you wanna do in the setting of disease 603 00:34:58,937 --> 00:35:01,097 is to under dose your GOAT. 604 00:35:01,427 --> 00:35:06,587 So you wanna make sure that you're supporting them with GCSF if necessary. 605 00:35:06,797 --> 00:35:10,307 Um, but you're not gonna decrease those doses. 606 00:35:10,907 --> 00:35:14,487 When we have had refractory disease, I think having maribavir 607 00:35:14,507 --> 00:35:16,247 available has been pretty amazing. 608 00:35:16,448 --> 00:35:20,550 It is more effective than the very, very toxic foscarnet. 609 00:35:21,000 --> 00:35:24,420 One of the things that I would highlight, however, is you got 610 00:35:24,420 --> 00:35:27,030 maybe one shot, uh, and maybe not. 611 00:35:27,420 --> 00:35:32,390 In those trials there was 28% development of resistance to your maribavir. 612 00:35:32,820 --> 00:35:37,280 So you wanna be really cautious to protect that and to not use it 613 00:35:37,280 --> 00:35:38,780 when the viral load is too high. 614 00:35:38,960 --> 00:35:42,050 I think those are cases where you're definitely gonna still see failure. 615 00:35:42,490 --> 00:35:46,460 We had hoped that maybe at doing adjunctive therapy, using more than 616 00:35:46,460 --> 00:35:51,890 one antiviral, like we do for our hyper mutable RNA viruses would be helpful. 617 00:35:51,890 --> 00:35:55,250 But in our group, we did not show that to be the case. 618 00:35:55,430 --> 00:35:58,130 So I'm not saying that you couldn't try it, but it wasn't 619 00:35:58,130 --> 00:35:59,990 effective when we trialed that. 620 00:36:00,320 --> 00:36:04,730 So I think maribavir is a fabulous new drug to have in the armamentarium. 621 00:36:04,940 --> 00:36:06,680 Think about the viral load. 622 00:36:06,860 --> 00:36:11,390 Again, the viral load tells you how much replication is going on, and every time 623 00:36:11,390 --> 00:36:14,360 there's replication going on, there's the chance for mutation every day. 624 00:36:14,660 --> 00:36:18,940 So, the lower the viral load, the less chance for a mutation, the safer 625 00:36:18,940 --> 00:36:20,730 it is to use a drug like maribavir. 626 00:36:21,100 --> 00:36:26,530 That's even further for letermovir, which is why we use it for prophylaxis. 627 00:36:26,560 --> 00:36:30,250 As it turns out, that has a small, very low barrier to resistance. 628 00:36:30,460 --> 00:36:34,360 And so even very low viral loads will break through with resistance. 629 00:36:34,690 --> 00:36:38,770 So I, I think the, the goal should always be to never develop a drug 630 00:36:38,770 --> 00:36:44,240 resistant CMV, because once that happens, it's really hard for the patient. 631 00:36:44,600 --> 00:36:47,990 But I am glad that we have options like we do now. 632 00:36:48,465 --> 00:36:48,795 Samira Farouk: Thanks. 633 00:36:48,885 --> 00:36:52,535 And, uh, this is a question for both teams, BK and CMV, what are your 634 00:36:52,535 --> 00:36:58,475 thoughts about IV immunoglobulin for either, is there a role for them? 635 00:36:58,963 --> 00:37:00,342 Jeannina Smith: My students will tell you what I say. 636 00:37:00,422 --> 00:37:01,562 I call it witchcraft. 637 00:37:01,782 --> 00:37:04,904 We do it sometimes, but it's not really that different than waving 638 00:37:04,904 --> 00:37:06,614 a chicken foot over the patient. 639 00:37:06,817 --> 00:37:11,137 I will say one thing that I like about it when we use, uh, IV immunoglobulin 640 00:37:11,347 --> 00:37:16,007 is that at least for antibody mediated rejection, there's some prevention 641 00:37:16,007 --> 00:37:17,417 when we're using immunoglobulin. 642 00:37:17,657 --> 00:37:22,997 And so as I'm begging the transplant nephrologist to drop that anti 643 00:37:22,997 --> 00:37:27,107 metabolite off and perhaps reduce the immunosuppression further than 644 00:37:27,107 --> 00:37:30,077 that, um, I think it makes us all a little more comfortable that we 645 00:37:30,077 --> 00:37:31,667 have a little protection on board. 646 00:37:31,857 --> 00:37:36,967 But I don't think that antibody or B cell is the major feature 647 00:37:37,237 --> 00:37:39,997 of immunity to CMV or frankly BK. 648 00:37:40,147 --> 00:37:44,197 And so I don't see it being reasonable that those would have a big role. 649 00:37:45,197 --> 00:37:47,207 Sara, do you like 'em or do you, do you use them? 650 00:37:48,478 --> 00:37:49,783 Sara Dong: Um, I agree. 651 00:37:49,783 --> 00:37:53,473 I think sometimes we use them just because. 652 00:37:53,473 --> 00:37:57,673 I mean, I think for patients that you are suspicious or maybe they have hypogam for 653 00:37:57,673 --> 00:37:59,583 other reasons, like looking at their IgG 654 00:37:59,657 --> 00:37:59,897 Jeannina Smith: Absolutely. 655 00:38:00,053 --> 00:38:01,293 Sara Dong: and repleting them. 656 00:38:01,853 --> 00:38:03,673 To me, those make the most sense. 657 00:38:03,673 --> 00:38:05,593 But I, I agree. 658 00:38:05,593 --> 00:38:08,573 I think there are times where we're using them, a little more 659 00:38:08,573 --> 00:38:10,373 sort of willy-nilly than that. 660 00:38:10,673 --> 00:38:10,973 So. 661 00:38:11,445 --> 00:38:12,930 Jeannina Smith: They're, they're wishful thinking. 662 00:38:14,166 --> 00:38:17,916 Samira Farouk: Caitlin, did you find anything to support use of IVIG in 663 00:38:17,916 --> 00:38:20,826 patients with BK viremia, BK nephropathy? 664 00:38:22,896 --> 00:38:24,321 Caitlyn Vlasschaert: Um, not much. 665 00:38:24,381 --> 00:38:27,981 Uh, I think we included one link to something that 666 00:38:28,091 --> 00:38:28,211 Samira Farouk: I, 667 00:38:28,221 --> 00:38:30,891 Caitlyn Vlasschaert: had found, but honestly not much. 668 00:38:31,026 --> 00:38:32,046 Samira Farouk: I kind of set you up for that. 669 00:38:32,046 --> 00:38:33,696 I heard the papers kind of rustling. 670 00:38:33,796 --> 00:38:38,010 There's very little, and, you know, I think that sometimes, people just can't 671 00:38:38,010 --> 00:38:42,270 resist themselves and, you know, we've lowered all the immunosuppression. 672 00:38:42,270 --> 00:38:44,610 They're on barely anything and we have nothing else. 673 00:38:44,610 --> 00:38:46,710 So let's just give some IVIG. 674 00:38:47,040 --> 00:38:50,190 Um, and I, and I think, you know, most of the time we see no, you 675 00:38:50,190 --> 00:38:54,100 know, quote harm, but we actually did recently, in our center see a patient 676 00:38:54,100 --> 00:38:58,925 that we think developed a TMA from IVIG, which has been, uh, reported. 677 00:38:58,925 --> 00:39:03,485 So I think, uh, very few things are completely without any potential harm. 678 00:39:03,875 --> 00:39:04,165 Sara Dong: Yeah. 679 00:39:05,400 --> 00:39:09,350 Jeannina Smith: Yeah, I've for sure, um, seen patients get meningitis from 680 00:39:09,350 --> 00:39:15,220 IVIG that was given in this setting and aseptic, but it certainly affected 681 00:39:15,220 --> 00:39:18,140 their, how they felt and it's sad. 682 00:39:18,758 --> 00:39:22,088 Samira Farouk: Um, so Sam is our expert for the BK team. 683 00:39:22,118 --> 00:39:26,288 Sam, can you give us your take on what do you think is the current state of 684 00:39:26,498 --> 00:39:31,598 BK treatment and how do you predict our new therapies are going to change 685 00:39:31,598 --> 00:39:33,938 how we are able to deal with BK? 686 00:39:35,183 --> 00:39:35,473 Sam Kant: Well. 687 00:39:35,778 --> 00:39:36,678 Know, to be honest. 688 00:39:36,708 --> 00:39:41,885 Um, I always look at BK as, you know, one of those things that tells you that you're 689 00:39:41,885 --> 00:39:43,625 actually immunosuppressing a lot more. 690 00:39:43,775 --> 00:39:46,935 You know, I, you know, trainees always ask me, how, how do we 691 00:39:46,935 --> 00:39:50,565 really make sure that we're actually immunosuppressing well or less? 692 00:39:50,895 --> 00:39:52,905 It's a nice surrogate, I feel in many ways. 693 00:39:53,586 --> 00:39:57,096 And then once you have it, you kind of know you need to kind of really pull back. 694 00:39:57,096 --> 00:40:01,266 Of course, it's very obvious, but I think the steps in which people go about it can 695 00:40:01,266 --> 00:40:05,786 be very diverse, but the best evidence is pull back on the anti-metabolites 696 00:40:05,786 --> 00:40:06,956 and then kind of take it from there. 697 00:40:07,801 --> 00:40:10,066 I, I think we've had a good discussion on IVIG. 698 00:40:10,163 --> 00:40:14,393 You know, I think that's probably the best that's out there if you, if your 699 00:40:14,393 --> 00:40:16,373 immunosuppression reduction isn't working. 700 00:40:16,803 --> 00:40:19,833 I think there's another, a lot of studies from France that, you know, they've 701 00:40:19,833 --> 00:40:24,303 actually looked at neutralizing antibodies that IVIG actually contains, because, you 702 00:40:24,303 --> 00:40:26,193 know, you're exposed to it as a child. 703 00:40:26,443 --> 00:40:30,643 Where I think 90% of, um, children would be seropositive at some 704 00:40:30,643 --> 00:40:32,013 point, based on many studies. 705 00:40:32,013 --> 00:40:35,583 But coming to the future, I do think there's promise anyway. 706 00:40:35,583 --> 00:40:39,393 Now they're developing, um, you know, whether it's various viruses 707 00:40:39,573 --> 00:40:41,823 that actually act against, uh, BK. 708 00:40:41,823 --> 00:40:44,673 But I think it's about just keeping it simple, you know, I mean, making 709 00:40:44,673 --> 00:40:48,063 sure you reduce the immunosuppression at the right time and above all, 710 00:40:48,523 --> 00:40:52,813 have good surveillance, you know, um, we really get enthralled by new 711 00:40:52,813 --> 00:40:57,253 therapies when, uh, simplicity might be the best form of sophistication. 712 00:40:57,741 --> 00:40:58,401 Samira Farouk: Yeah, KISS. 713 00:40:58,401 --> 00:40:59,691 Keep it simple, stupid. 714 00:40:59,751 --> 00:41:02,721 That's the, maybe the punchline for both of these teams 715 00:41:02,746 --> 00:41:03,341 Sam Kant: There you go. 716 00:41:04,078 --> 00:41:06,808 Samira Farouk: As we kind of wrap up or get close to the end here, 717 00:41:06,888 --> 00:41:10,878 thinking about how do we surveil how immunosuppressed somebody is, would 718 00:41:10,878 --> 00:41:13,958 love to hear anybody's thoughts on something I'm really excited to be able 719 00:41:13,958 --> 00:41:16,088 to use in practice, torque teno virus. 720 00:41:16,118 --> 00:41:17,918 What do we think about torque teno virus? 721 00:41:18,199 --> 00:41:18,979 Sam Kant: I'll jump in. 722 00:41:19,189 --> 00:41:23,846 To be honest, it's promising for sure, uh, but I don't think we've studied 723 00:41:23,846 --> 00:41:27,486 it enough to really come forward and say, this is what it is, I think. 724 00:41:28,211 --> 00:41:32,981 You know, they've employed using it in, in guiding immunosuppression as you state, 725 00:41:32,981 --> 00:41:35,141 but you know, what are the outcomes? 726 00:41:35,141 --> 00:41:36,731 You know, is does this really help? 727 00:41:36,731 --> 00:41:40,841 To, to, to really, um, you know, what, how often would you check it? 728 00:41:41,381 --> 00:41:44,231 And how would it perform in different immunosuppression regimes? 729 00:41:44,231 --> 00:41:46,841 I think so many unanswered questions. 730 00:41:47,154 --> 00:41:52,474 Again, I think, uh, our good old BK, is, is enough I feel on that front, you know. 731 00:41:53,394 --> 00:41:56,074 Why forget the, the, the old and gold, you know. 732 00:41:56,783 --> 00:42:00,323 Samira Farouk: All right, so another Neph madness, BK versus, uh, TTV. 733 00:42:00,353 --> 00:42:01,883 We'll see, uh, how it goes. 734 00:42:02,273 --> 00:42:04,913 Um, ID, uh, experts. 735 00:42:05,159 --> 00:42:07,299 Are you excited about TTV? 736 00:42:07,319 --> 00:42:10,589 Are you just like Sam, not as excited. 737 00:42:10,589 --> 00:42:10,649 I. 738 00:42:10,758 --> 00:42:12,378 Jeannina Smith: I say I'll believe it when I see it. 739 00:42:12,478 --> 00:42:17,818 I was always taught that when you see a lot of new, uh, articles saying 740 00:42:17,818 --> 00:42:21,448 that this is the new way to diagnose ventilator associated pneumonia, this 741 00:42:21,448 --> 00:42:25,348 is gonna be the new way to hit the sweet spot for immunosuppression. 742 00:42:25,468 --> 00:42:27,268 That probably means we haven't gotten there yet. 743 00:42:27,508 --> 00:42:30,448 So we get the data, that'll be great. 744 00:42:30,658 --> 00:42:33,508 I love the idea of my patients being optimally. 745 00:42:33,508 --> 00:42:34,738 Im immunosuppressed. 746 00:42:34,738 --> 00:42:37,848 Maybe it's like from our discussion early, the car commercial where 747 00:42:37,848 --> 00:42:39,768 the car parallel parks itself. 748 00:42:40,008 --> 00:42:43,518 That'd be super, um, but, I think I'll believe it when I see it. 749 00:42:43,678 --> 00:42:44,628 What about you, Sara? 750 00:42:44,764 --> 00:42:45,559 Sara Dong: Yeah, I agree. 751 00:42:45,559 --> 00:42:48,619 I, I don't know that we know quite how to use it yet. 752 00:42:48,619 --> 00:42:51,259 I think we're a little bit closer to hopefully knowing how to use 753 00:42:51,469 --> 00:42:53,989 CMV specific immunity assays. 754 00:42:54,349 --> 00:42:58,219 I will fully admit, I still think there's more to learn there on 755 00:42:58,219 --> 00:43:04,309 exactly how we can use that to decide you know, prophylaxis and, and who 756 00:43:04,408 --> 00:43:04,678 Jeannina Smith: Yeah, 757 00:43:04,759 --> 00:43:05,749 Sara Dong: take off or not. 758 00:43:05,749 --> 00:43:09,529 But I think that's something I've tried to bring into my practice, at 759 00:43:09,529 --> 00:43:14,479 least for more challenging cases as one other piece of data to try and 760 00:43:14,479 --> 00:43:20,399 help make a specific plan when those typical, you know, algorithms don't, 761 00:43:20,399 --> 00:43:22,769 don't help you manage things like CMV. 762 00:43:23,789 --> 00:43:28,739 So hopeful that feels sooner on the, on the timeline as far as 763 00:43:28,739 --> 00:43:30,929 incorporating into everyday practice. 764 00:43:31,108 --> 00:43:31,363 Jeannina Smith: I agree. 765 00:43:32,188 --> 00:43:32,488 Samira Farouk: All right. 766 00:43:32,488 --> 00:43:36,238 Maybe before we get to our final votes, anything else y'all wanna 767 00:43:36,238 --> 00:43:40,278 share about any of these two teams that we haven't highlighted? 768 00:43:41,178 --> 00:43:43,638 One thing that we haven't talked about is the origin of the names, uh, which 769 00:43:43,638 --> 00:43:45,211 I think both are, fairly interesting. 770 00:43:45,241 --> 00:43:49,691 Uh, BK named for the Sudanese patient from whom it was isolated 771 00:43:49,691 --> 00:43:54,281 in the UK and cytomegalovirus, cyto for cell, mega for big. 772 00:43:54,281 --> 00:43:58,411 So referring to those big owl eyes that we see on histopathology. 773 00:43:58,831 --> 00:44:02,101 Jeannina Smith: I would like to point out that the JC virus, the other polyoma 774 00:44:02,101 --> 00:44:07,051 virus, was named from a patient at the Madison VA Hospital, John Cunningham. 775 00:44:07,291 --> 00:44:13,121 So, uh, I feel like a little, uh, special link to those polyoma viruses. 776 00:44:13,601 --> 00:44:15,041 I would also like to point out. 777 00:44:16,166 --> 00:44:16,946 Google it. 778 00:44:17,006 --> 00:44:21,556 It's always interesting, which person thinks owl's eyes is in their particular 779 00:44:21,556 --> 00:44:26,266 purview because the hematologists love to think about their Hodgkin's owl's eyes, 780 00:44:26,446 --> 00:44:32,316 whereas an ID doctor, I have a particular partiality to CMV megaloblastic cells. 781 00:44:32,316 --> 00:44:34,571 Samira Farouk: We have a similar issue with the Maltese cross. 782 00:44:34,571 --> 00:44:35,271 Also a hematology 783 00:44:35,300 --> 00:44:35,720 Jeannina Smith: Oh yes. 784 00:44:35,720 --> 00:44:36,020 Fabrys. 785 00:44:36,281 --> 00:44:37,091 Samira Farouk: problem. 786 00:44:37,121 --> 00:44:37,631 Yeah. 787 00:44:38,690 --> 00:44:41,475 Jeannina Smith: We have that in ID too though, 'cause that's Babesia for us. 788 00:44:42,356 --> 00:44:45,416 Samira Farouk: Yeah, for us it's the fatty oval body when you polarize 789 00:44:45,416 --> 00:44:49,286 it in patients that have lipiduria, and, um, nephrotic syndrome. 790 00:44:49,296 --> 00:44:49,566 all right. 791 00:44:49,566 --> 00:44:50,046 Very cool. 792 00:44:50,046 --> 00:44:53,426 So, most important question, how are you feeling at your bracket? 793 00:44:53,426 --> 00:44:56,186 I think people are maybe a little bit biased, but we'll see. 794 00:44:56,456 --> 00:45:00,576 Um, so we'll just maybe go around the horn here and, uh, tell us who you're 795 00:45:00,576 --> 00:45:04,806 voting for in this bracket and why you think they are the better team. 796 00:45:05,106 --> 00:45:08,166 Um, so maybe, uh, we'll start with Sara because, 797 00:45:08,406 --> 00:45:08,976 Sara Dong: Oh, no. 798 00:45:09,066 --> 00:45:11,016 Samira Farouk: the least skin in the game here. 799 00:45:12,459 --> 00:45:15,569 Sara Dong: Um, I mean, I have to vote CMV here. 800 00:45:15,569 --> 00:45:18,909 I don't, I don't know if it's just as an ID doctor. 801 00:45:18,909 --> 00:45:24,609 I, I think about, talk about, see CMV every day, and there's just so many new 802 00:45:24,609 --> 00:45:28,479 things I feel like we're on the cusp of really understanding in the coming years. 803 00:45:28,479 --> 00:45:30,369 So that's, that's my pick. 804 00:45:31,089 --> 00:45:31,684 Samira Farouk: All right, Sam. 805 00:45:33,489 --> 00:45:35,529 Sam Kant: Um, I think, I think you know the answer to that 806 00:45:35,529 --> 00:45:37,359 for me, it's BK of course. 807 00:45:37,479 --> 00:45:42,669 Um, you know, as much as I have to say CMV is, um, definitely a, I have a 808 00:45:42,669 --> 00:45:46,089 little more interesting when it comes to management, a little more because 809 00:45:46,089 --> 00:45:47,979 you have more things to treat it with. 810 00:45:48,519 --> 00:45:53,549 Um, but you know, I, as I said, you know, it's, it's such a good surrogate for how 811 00:45:53,549 --> 00:45:55,079 well you're doing with immunosuppression. 812 00:45:55,709 --> 00:46:00,389 Um, and above all, you know, I think, um, if you catch it early, you really, you 813 00:46:00,389 --> 00:46:04,249 really make sure that patient outcomes and graft outcomes are excellent. 814 00:46:04,779 --> 00:46:06,549 But then, we can really treat it well. 815 00:46:06,549 --> 00:46:08,349 You know, once you get a really good handle on it. 816 00:46:08,349 --> 00:46:12,319 CMV, if you don't have a good handle on it, can really, really, um, go through 817 00:46:12,319 --> 00:46:17,209 it, but I think why I feel more aff affinity towards BK if that, if I could 818 00:46:17,209 --> 00:46:21,979 use that term, is, um, I mean I think I've really enjoyed, uh, in, in transplant 819 00:46:21,979 --> 00:46:25,879 nephrology from the start and probably my mentors that I've had, uh, have really 820 00:46:25,879 --> 00:46:28,759 pushed me in that direction, you know, and I, so it's, I think it's an ode to 821 00:46:28,759 --> 00:46:30,619 my mentors rather than anything else. 822 00:46:30,619 --> 00:46:33,439 Um, that's why I think I choose BK as well. 823 00:46:33,894 --> 00:46:35,034 Samira Farouk: All right, Jeannina, you're up. 824 00:46:36,863 --> 00:46:39,083 Jeannina Smith: I mean, on. 825 00:46:39,143 --> 00:46:39,713 Of course. 826 00:46:39,713 --> 00:46:40,313 I think so. 827 00:46:40,313 --> 00:46:45,743 CMV is the most common opportunistic infection after transplant. 828 00:46:46,133 --> 00:46:48,113 It's tremendously impactful. 829 00:46:48,413 --> 00:46:53,003 We've had a bevy of new drugs available in our armamentarium. 830 00:46:53,498 --> 00:46:57,398 We have improved outcomes for hundreds of thousands, if 831 00:46:57,398 --> 00:46:58,928 not millions of our patients. 832 00:46:59,198 --> 00:47:07,058 Uh, I think without question, one has to give the love to our favorite, 833 00:47:07,058 --> 00:47:08,738 least favorite herpes virus. 834 00:47:08,738 --> 00:47:09,308 CMV. 835 00:47:11,354 --> 00:47:12,344 Samira Farouk: Strong words. 836 00:47:12,344 --> 00:47:15,734 Uh, Caitlyn, you can see how you can fight that. 837 00:47:16,071 --> 00:47:16,491 Caitlyn Vlasschaert: Yeah. 838 00:47:16,491 --> 00:47:18,381 So I mean, it's a tough call for me. 839 00:47:18,381 --> 00:47:22,041 I feel some amount of allegiance to BK, um, having contributed 840 00:47:22,041 --> 00:47:23,151 a bit more to that section. 841 00:47:23,151 --> 00:47:26,871 But I, I do think ultimately that's probably gonna be my pick mainly 842 00:47:26,871 --> 00:47:31,131 because it's, I see it in some ways as sort of the nephrologist virus. 843 00:47:31,131 --> 00:47:34,611 Like we're sort of the only ones that really see it and then treat it 844 00:47:34,611 --> 00:47:36,321 and then, you know, think about it. 845 00:47:36,321 --> 00:47:41,721 Whereas CMV again, devastating, lots more morbidity, mortality, I think in general, 846 00:47:41,721 --> 00:47:46,821 associate not just thinking about graft loss, but it, it feels something special 847 00:47:46,821 --> 00:47:49,971 that we sort of hold and, and watch for. 848 00:47:49,971 --> 00:47:51,531 So I, I like that side of it. 849 00:47:51,891 --> 00:47:55,311 Sam Kant: Yeah, it is Neph Madness in the end, you know, so we, we take ownership, 850 00:47:55,731 --> 00:47:57,561 we take ownership for what we look after. 851 00:47:57,561 --> 00:48:00,591 So that's BK, you know, come on. 852 00:48:00,661 --> 00:48:02,031 Samira Farouk: The bracket is devolving a little bit. 853 00:48:02,301 --> 00:48:03,861 Sam Kant: Yes, yes. 854 00:48:03,861 --> 00:48:07,711 You know, I mean, uh, I know I've, I have a lot of, I've, I've, I, I 855 00:48:07,711 --> 00:48:11,001 have to say, I have a lot of love and respect for ID physicians, so I do. 856 00:48:11,031 --> 00:48:14,841 That's why I do like CMV quite a bit, but yes, let's, let's own what we have. 857 00:48:14,841 --> 00:48:15,771 You know, it's BK 858 00:48:18,206 --> 00:48:18,876 Samira Farouk: Hari, go ahead. 859 00:48:20,741 --> 00:48:23,721 Hariharasudan Natarajan: So, um, my vote would be for CMV. 860 00:48:23,736 --> 00:48:27,806 Uh, as Dr. Smith mentioned, the most commonest opportunistic infection. 861 00:48:28,176 --> 00:48:32,046 And something I found really fascinating or something that I learned during 862 00:48:32,046 --> 00:48:36,066 this whole process of writing was that CMV is not just infection, 863 00:48:36,066 --> 00:48:37,956 it's an, it's immunomodulatory. 864 00:48:38,476 --> 00:48:43,926 It has impact on the graft outcomes, and interestingly also increases the 865 00:48:43,926 --> 00:48:49,176 risk for other opportunistic infections, like aspergillus and pneumocystis. 866 00:48:49,446 --> 00:48:53,916 Uh, so it has major transplant outcomes and it is preventable. 867 00:48:54,186 --> 00:48:56,196 And we also have options for treatment. 868 00:48:56,466 --> 00:49:01,266 So that would be my pick for, uh, this year's winner for Neph Madness. 869 00:49:01,671 --> 00:49:05,718 Samira Farouk: I am gonna put in my vote, if I'm, uh, I think, uh, I guess I'm 870 00:49:05,718 --> 00:49:07,458 the tiebreaker kind of, or maybe not. 871 00:49:07,758 --> 00:49:11,668 Um, I'm picking this not because nephrology versus ID. 872 00:49:11,733 --> 00:49:13,533 Um, I'm gonna vote for BK. 873 00:49:13,893 --> 00:49:18,793 Um, the reason is that it is such a Achilles heel in many ways for 874 00:49:18,793 --> 00:49:20,353 our kidney transplant recipients. 875 00:49:20,353 --> 00:49:23,533 And, um, it's so challenging to tell patients that they're 876 00:49:23,533 --> 00:49:27,013 losing their allograft for this completely silent virus. 877 00:49:27,013 --> 00:49:29,533 That is I just learned, uh, today that is so tiny. 878 00:49:29,533 --> 00:49:31,003 I didn't realize that it was so small. 879 00:49:31,333 --> 00:49:33,543 Um, and sometimes, we do the biopsy. 880 00:49:33,603 --> 00:49:37,773 We know there's BK viremia, we're almost hoping to find something else because 881 00:49:37,773 --> 00:49:41,883 we've lowered the immunosuppression and there's nothing but just rip roaring 882 00:49:42,123 --> 00:49:44,403 BK related interstitial nephritis. 883 00:49:44,433 --> 00:49:48,158 And we have nothing to do, uh, but maybe kinda reach for IVIG. 884 00:49:48,183 --> 00:49:52,363 And this vote is for, for hope, hopeful for better treatments for BK, for patients 885 00:49:52,363 --> 00:49:54,133 in whom immunosuppression doesn't work. 886 00:49:54,523 --> 00:49:59,863 Um, and then once we, uh, eradicate BK, I'm happy to focus my attention to CMV. 887 00:50:03,401 --> 00:50:04,301 Sara Dong: Excellent. 888 00:50:04,481 --> 00:50:09,161 Well, I am so excited to see how the bracket ends up, how this region does. 889 00:50:09,401 --> 00:50:13,361 There are a few practical things that we talked about today that I'll summarize, 890 00:50:13,407 --> 00:50:18,387 but I'd love to just first emphasize how these infections really highlight how 891 00:50:18,387 --> 00:50:21,492 transplant teams are multidisciplinary. 892 00:50:21,882 --> 00:50:24,402 I can of course speak from my experiences. 893 00:50:24,402 --> 00:50:28,902 You know, I love working together, ID, nephrology, we mentioned our 894 00:50:28,902 --> 00:50:33,462 pharmacy colleagues and really the entire transplant team. 895 00:50:33,727 --> 00:50:36,857 So, thinking through a few takeaways. 896 00:50:36,977 --> 00:50:40,367 First, screening early and acting early. 897 00:50:40,427 --> 00:50:46,097 You know, both BK and CMV tend to give you a window of warning before damage 898 00:50:46,097 --> 00:50:48,751 happens, sometimes irreversible damage. 899 00:50:48,751 --> 00:50:51,541 And so what you do in that window really matters. 900 00:50:51,821 --> 00:50:55,661 Next, we know that reduction in immunosuppression really remains 901 00:50:55,661 --> 00:50:59,537 the cornerstone, and no matter how sophisticated our diagnostics 902 00:50:59,537 --> 00:51:03,677 or therapeutics become, restoring immunity is still the foundation 903 00:51:03,737 --> 00:51:05,537 of care for these patients. 904 00:51:05,977 --> 00:51:09,397 Next, we talked a little bit about how CMV and BK really live 905 00:51:09,397 --> 00:51:11,737 in different therapeutic worlds. 906 00:51:11,887 --> 00:51:17,977 CMV has a toolbox of effective antivirals, which are continuing to 907 00:51:17,977 --> 00:51:23,214 expand, but BK, at least for now, really just fundamentally requires immune 908 00:51:23,214 --> 00:51:25,844 restoration rather than antivirals. 909 00:51:26,444 --> 00:51:31,334 And finally, biomarkers and immune-based therapies are hopefully 910 00:51:31,334 --> 00:51:32,894 where the field may be heading. 911 00:51:33,224 --> 00:51:38,354 They won't replace our clinical judgment, but they may help us move from making, 912 00:51:38,462 --> 00:51:43,836 more sort of blunt adjustments and proceed to more personalized care. 913 00:51:44,222 --> 00:51:50,612 So get out there, submit your own and group brackets for Neph Madness 2026. 914 00:51:50,656 --> 00:51:55,042 The brackets are open now and submissions will close on March 31st. 915 00:51:55,072 --> 00:51:58,302 Thanks again to our excellent guides and authors, Hari and 916 00:51:59,139 --> 00:52:03,009 as well as Jeannina, and Sam. 917 00:52:03,237 --> 00:52:07,287 You can check out the website, febrile podcast.com, where we keep the Consult 918 00:52:07,287 --> 00:52:10,911 Notes, which are written supplements of the episodes with links to references, 919 00:52:10,931 --> 00:52:13,931 our library of ID infographics, and a link to our merch store. 920 00:52:14,651 --> 00:52:17,411 Febrile is produced with support from the Infectious Diseases 921 00:52:17,411 --> 00:52:19,271 Society of America, IDSA. 922 00:52:19,961 --> 00:52:23,111 Please reach out if you have any suggestions for future shows or 923 00:52:23,111 --> 00:52:24,761 wanna be more involved with Febrile. 924 00:52:24,971 --> 00:52:25,781 Thanks for listening. 925 00:52:26,051 --> 00:52:27,671 Stay safe and I see you next time.